Résumé
To assess the effects of tamoxifen therapy in breast cancer patients on the endometrium. Study was conducted on 30 tamoxiten treated and 10 non-treated breast cancer patients who already were surgically treated. Cases and controls were matching regarding age, parity and time since menopause. Thorough clinical and Laboratory assessment was done. Cases and controls were subjected to transvaginal sonography [TVS] and diagnostic curettage. In tamoxiten group: there was significant increase in uterine volume and endometrial thickness. Significant increase in the incidence of endometrial changes was found: 46.7% atrophic endometrium, 13.3% proliferative endometrium, 13.3% simple hyperplasia, 13.3% cystic hyperplasia, 3.3% adenomatous hyperplasia and 10% endometrial polypi. No single case of atypical hyperplasia nor endometrial carcinoma was found. Tamoxifen treated breast cancer patients have increased risk of endometrial hyperplasia and polypi. Hyperplasia being the forerunner of endometrial cancer, such patients should be allotted to the high risk groups for endometrial cancer